Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: Exploring the evidence, guidelines, and challenges remaining;Warfarina Para la Profilaxis del Tromboembolismo Venoso Después de una Artroplastia Electiva de Cadera o de Rodilla: Examen de la Evidencia, las Directrices, y los Retos Que Quedan

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages 79-88

  Dager, William E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Orthopedic surgery; Total hip arthroplasty; Total knee arthroplasty; Venous thromboembolism; Vitamin K antagonists; Warfarin

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; ARDEPARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; NADROPARIN; TINZAPARIN; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; HUMAN; MEDICAL SOCIETY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL TRIALS AS TOPIC; HUMANS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84855705838     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P626     Document Type: Article

References (65)

1. Wang Y, Simpson JA, Wluka AE, et al. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis Res Ther 2009;11:1-10.
2. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49.
3. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008;28:387-91.
4. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(suppl):381S-453S.
5. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-5.
6. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:1037-52.
7. Comp PC, Voegeli T, McCutchen JW, et al. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: the Danaparoid Hip Arthroplasty Investigators Group. Orthopedics 1998;21:1123-8.
8. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest 1998;114(suppl):115S-8S.
9. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
10. Lang I. Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. Br J Haematol 2010;149:478-83.
11. Meissner MH, Wakefield TW, Ascher E, et al. Acute venous disease: venous thrombosis and venous trauma. J Vasc Surg 2007;46(Suppl S):25S-53S.
12. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994;76:3-14.
13. Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: metaanalysis based on original patient data. Thromb Res 2001;102:295-309.
14. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-10.
15. Colwell CW Jr, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003;1:2119-30.
16. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
17. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-6.
18. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-96.
19. Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a metaanalysis. J Thromb Haemost 2004;2:1058-70.
20. Johanson NA, Lachiewicz PF, Lieberman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Am Acad Orthop Surg 2009;17:183-96.
21. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. www.aaos.org/Research/guidelines/PE_guideline.pdf (accessed 2010 Sep 24).
22. American Academy of Orthopaedic Surgeons guideline on preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. http://www.aaos.org/research/guidelines/VTE/VTE_guideline.asp (accessed 2011 Nov 3).
23. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009;135:513-20
24. Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995;80:299-306.
25. Bauer K. The Pentamaks study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective major knee surgery (Abstract 2111). Blood 2000;96:490.
26. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40.
27. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2199-207.
28. Turpie G. The Pentathlon 2000 study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery (Abstract 2112). Blood 2000;96:491.
29. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty. Arch Intern Med 2002;162:1966-71.
30. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
31. What is SCIP? Premier Surgical Care Improvement Project (SCIP). http://www.premierinc.com/safety/topics/scip/index.jsp (accessed 2010 Sep 24).
32. Medicare announces sites for pilot program to improve quality as patients move across care settings (press release). Centers for Medicare & Medicaid Services. http://www.cms.hhs.gov/apps/media/press/release.asp?Counter=3439&intNumPerPage=10&checkDate=&checkKey=2&srchType=2&numDays=0&srchOpt=0&srchData=move+across+care+settings&keywordType=All&chkNewsType=1%2C+2%2C+3%2C+4%2C+5&intPage=&showAll=1&pYear=1&year=2009&desc=&cboOrder=date (accessed 2010 Sep 24).
33. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994;76:1174-85.
34. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001;83:900-6.
35. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997;79:1365-72.
36. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-55.
37. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
38. Hamulyak K, Lensing AW, van der Meer J, et al. Subcutaneous lowmolecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 1995;74:1428-31.
39. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost 1997;77:32-8.
40. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous lowmolecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
41. Colwell CW Jr, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005;87:2169-77.
42. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-26.
43. Hirsh J. Current anticoagulant therapy-unmet clinical needs. Thromb Res 2003;109(suppl 1):S1-8.
44. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/ out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2208-15.
45. Vives MJ, Hozack WJ, Sharkey PF, Moriarty L, Sokoloff B, Rothman RH. Fixed minidose versus adjusted low-dose warfarin after total joint arthroplasty. J Arthroplasty 2001;16:1030-7.
46. Anderson DR, Wilson J, Blundell J, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deepvein thrombosis after arthroplasty. J Bone Joint Am 2002;84:1992-7.
47. Sachs RA, Smith JH, Kuney M, Paxton L. Does anticoagulation do more harm than good? A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty 2003;18:389-95.
48. Woolson ST. Letter to the editor. J Arthroplasty 2003;19:132-3.
49. Bern M, Deshmukh RV, Nelson R, et al. Low-dose warfarin coupled with lower leg compression is effective prophylaxis against thromboembolic disease after hip arthroplasty. J Arthroplasty 2007;22:644-50.
50. Warwick D, Samama MM. The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. J Bone Joint Surg Br 2000;82:480-2.
51. Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002;87:515-22.
52. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-60.
53. Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009;150:577-85.
54. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009;7(suppl 1):9-12.
55. Dager W. Clinical outcomes using subcutaneous unfractionated heparin bridge to warfarin after elective total hip or knee arthroplasty (Abstract 48). Pharmacotherapy 2006;26:48.
56. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(suppl):160S-198S.
57. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87-97.
58. Nordstrom B, Kachroo S, Nutescu E, et al. Warfarin INR patterns following total knee arthroplasty (poster 38). Presented at: Society for Vascu-lar Medicine (SVM) 21st Annual Scientific Sessions 6th Annual Comprehensive Vascular Review Course, Cleveland, OH, April 28-May 2, 2010.
59. Kachroo S, Nordstrom B, Nutescu E, et al. Risk of venous thromboembolism as a function of international normalized ratio (INR) in total hip replacement (poster 21480). Presented at: the American College of Clinical Pharmacy 2010 Spring Practice and Research Forum, Charlotte, NC, April 23-27, 2010.
60. Lefebvre P, Vekeman F, Nutescu E, et al. Incidence rate of venous thromboembolism and hemorrhage in patients undergoing total hip or knee arthroplasty: a managed care perspective (poster 749477). Presented at: the Academy of Managed Care Pharmacy (AMCP) 22nd Annual Meeting and Showcase, San Diego, CA, April 7-10, 2010.
61. Lin PJ. Reviewing the reality: why we need to change. Eur Heart J Suppl 2005;7(suppl E):E15-E20.
62. Hamby L, Weeks WB, Malikowski C. Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic. Eff Clin Pract 2000;3:179-84.
63. Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy 2011;31:686-94.
64. Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 2009;66:123-33.
65. Wu AH. Pharmacogenomic testing for warfarin dosing: we are ready now. Expert Rev Cardiovasc Ther 2009;7:1483-5.